Discontinued — last reported Q4 '25
Accounts Receivable
Current AssetsEli Lilly Accounts Receivable increased by 10.3% to $17.76B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 61.4%, from $11.01B to $17.76B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 24.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2008
Last reportedQ4 2025
How to read this metric
An increase relative to revenue may signal slowing collections or aggressive sales terms; a decrease suggests efficient billing and collection cycles.
Detailed definition
The total amount of credit extended to customers for products and services already delivered, adjusted for potential bad...
Peer comparison
Enterprise-focused peers like Oracle or SAP show similar patterns based on quarterly sales cycles.
Metric ID:
accounts_receivable_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.83B | $5.91B | $6.67B | $6.32B | $6.36B | $6.72B | $6.90B | $7.53B | $7.52B | $8.17B | $9.09B | $7.89B | $11.03B | $10.29B | $11.01B | $12.04B | $14.17B | $16.11B | $17.76B |
| QoQ Change | — | +1.5% | +12.8% | -5.2% | +0.7% | +5.5% | +2.7% | +9.1% | -0.1% | +8.7% | +11.3% | -13.3% | +39.8% | -6.6% | +6.9% | +9.4% | +17.7% | +13.7% | +10.3% |
| YoY Change | — | — | — | — | +9.2% | +13.5% | +3.3% | +19.0% | +18.1% | +21.6% | +31.8% | +4.8% | +46.7% | +26.1% | +21.1% | +52.6% | +28.5% | +56.5% | +61.4% |
Range$5.83B – $17.76B
CAGR+28.1%
Avg YoY Growth+27.6%
Median YoY Growth+21.6%
Current Streak5 quarters growth
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Eli Lilly's accounts receivable?
- Eli Lilly (LLY) reported accounts receivable of $17.76B in Q4 2025.
- How has Eli Lilly's accounts receivable changed year-over-year?
- Eli Lilly's accounts receivable increased by 61.4% year-over-year, from $11.01B to $17.76B.
- What is the long-term trend for Eli Lilly's accounts receivable?
- Over 5 years (2020 to 2025), Eli Lilly's accounts receivable has grown at a 24.8% compound annual growth rate (CAGR), from $5.88B to $17.76B.
- What does accounts receivable mean?
- Money owed to the company by customers who haven't paid their bills yet.